#cdk2 inhibitors

1 story

#breast cancer #business #clinical trials #durham #incyclix bio #ovarian cancer #precision oncology #startups

Durham's Incyclix Bio Raises $52M for Gentler Cancer Therapies
Incyclix Bio secures $52M to develop less toxic cancer treatments for breast and ovarian cancers.
Dealroom · 1m